适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •1. Subject has signed and dated the Patient Informed Consent/Patient Information Sheet
- •2. Subject is minimum 18 years of age at the time of informed consent
- •4. Subject is willing and available toattend visits as scheduled and to comply with the study protocol
- •5. Subject is willing and able to undergo assessments as part of the evaluation for eligibility and endpoints
- •6. Subject is willing and able to use the external 4neurostimulator, recharging equipment (if applicable) and patient programmer per the schedule required by the protocol
- •7. Subject has been diagnosed with FBSS (i.e.)
- •- has had persistent pain for 6 months following most recent anatomically correct, succesful surgery AND
- •- there is no clear surgical target on postoperative MR scan correlating to subject's pain
- •8. Based on the opinion of the Principal Investigator, subject's back pain is considered intractable and has been adequately treated, as defined by: 'Subject has failed an apropriate trial of at least 3 different classes of back pain treatments (pharmaceutical and/or non-pharmaceutical)'
- •9. Based on the opinion of the implanting physician, subject is an appropriate implant candidate for the SQS system
排除标准
- •1.Subject has been or is currently being treated with spinal cord stimulation, subcutaneous nerve stimulation, peripheral nerve stimulation or an implantable intrathecal drug delivery system
- •3. Subject has evidence of an active disruptive psychiatric disorder that is significant enough to impact the perception of pain, compliance to intervention and/or ability to evaluate treatment outcome, as determined by the investigator
- •4. Subject has a pain condition unrelated to FBSS that is severe enough to overshadow the FBSS pain in the opinion of the investigator
- •5. Subject has evidence of spinal instability or anatomic compression that requires further surgery
- •6. Subject has had spinal fusion at more than 3 vertebral levels
- •7. Subject is currently enrolled in or plans to enroll in any current drug and/or device study that may confound the results of this study
- •8. Subject is allergic or has shown hypersensitivity to any materials of the device system which come in contact with the body
- •9. Subject has a history of coagulation disorder or lupus erythematosus
- •10. Subkect is involved in current litigation regarding back pain
研究者
相似试验
进行中(未招募)
不适用
未命名试验EUCTR2015-000142-29-FRCHU CLERMONT-FERRAND
进行中(未招募)
1 期
未命名试验EUCTR2021-001854-74-FRCHU de Clermont-Ferrand84
进行中(未招募)
1 期
未命名试验-MedDRA version: 21.1Level: PTClassification code 10068724Term: Antiviral treatmentSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2020-001806-42-ITSOCIETA' ITALIANA DI REUMATOLOGIA - SIR438
已完成
不适用
未命名试验NL-OMON40860Pluryn80
招募中
不适用
未命名试验alle kinderen met intermitternde IV-medicatie-NL-OMON48210Isala Klinieken252
